This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Homology Medicines (FIXX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Homology Medicines (FIXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Homology Medicines (FIXX) is Poised for a Turnaround After Losing 25.1% in 4 Weeks
by Zacks Equity Research
Homology Medicines (FIXX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Homology Medicines (FIXX) have performed compared to their sector so far this year.
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Supernus (SUPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is Homology Medicines (FIXX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Homology Medicines (FIXX) and Ono Pharmaceutical Co. (OPHLF) have performed compared to their sector so far this year.
Will Homology Medicines (FIXX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Homology Medicines (FIXX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Homology Medicines (FIXX) stock based on the movements in the options market lately.
Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 6.90% and 249.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.